Sangamo Therapeutics, Inc. (SGMO) Shares Gap Up to $12.90
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $12.15, but opened at $12.90. Sangamo Therapeutics shares last traded at $12.90, with a volume of 1032600 shares changing hands.
Several brokerages recently commented on SGMO. Wedbush reiterated a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a report on Wednesday. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a report on Wednesday. Jefferies Group LLC reiterated a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a report on Friday, October 13th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $17.40.
The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) EPS. sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.84 EPS for the current year.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.25, for a total value of $228,750.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director William R. Ringo sold 31,000 shares of the company’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the transaction, the director now owns 31,800 shares in the company, valued at $456,966. The disclosure for this sale can be found here. Insiders sold a total of 61,000 shares of company stock worth $899,220 over the last 90 days. Insiders own 5.50% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth approximately $118,000. Amalgamated Bank purchased a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth approximately $158,000. Blair William & Co. IL lifted its position in shares of Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 500 shares during the period. Aperio Group LLC purchased a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth approximately $108,000. Finally, Great West Life Assurance Co. Can lifted its position in shares of Sangamo Therapeutics by 150.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 7,667 shares during the period. 64.08% of the stock is owned by hedge funds and other institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.